Anthera Pharmaceuticals, Inc. (ANTH) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) from a hold rating to a buy rating in a research note issued to investors on Tuesday. Zacks Investment Research currently has $2.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
Several other research firms also recently issued reports on ANTH. ValuEngine upgraded Anthera Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, September 1st. HC Wainwright restated a buy rating and set a $3.00 price objective on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. Finally, Jefferies Group LLC restated a hold rating and set a $1.75 price objective (down previously from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $5.11.
Anthera Pharmaceuticals (NASDAQ ANTH) opened at 1.79 on Tuesday. The stock’s market capitalization is $19.52 million. Anthera Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $3.22. The firm’s 50-day moving average is $1.46 and its 200 day moving average is $1.39.
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $1.12. Equities research analysts anticipate that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Anthera Pharmaceuticals, Inc. (ANTH) Upgraded by Zacks Investment Research to Buy” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/11/anthera-pharmaceuticals-inc-anth-upgraded-by-zacks-investment-research-to-buy.html.
Several institutional investors and hedge funds have recently modified their holdings of the company. Sabby Management LLC increased its holdings in shares of Anthera Pharmaceuticals by 1,809.7% in the 1st quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 1,665,655 shares during the period. UBS Group AG increased its holdings in shares of Anthera Pharmaceuticals by 9.9% in the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 33,901 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Anthera Pharmaceuticals by 1,376.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 335,595 shares during the period. Institutional investors own 27.26% of the company’s stock.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Stock Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.